Search hospitals

>

Iowa

>

Des Moines

CCOP - Iowa Oncology Research Association

Claim this profile

Des Moines, Iowa 50309

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Pancreatic Cancer

Conducts research for Ovarian Cancer

Conducts research for Cancer

408 reported clinical trials

2 medical researchers

Photo of CCOP - Iowa Oncology Research Association in Des MoinesPhoto of CCOP - Iowa Oncology Research Association in Des MoinesPhoto of CCOP - Iowa Oncology Research Association in Des Moines

Summary

CCOP - Iowa Oncology Research Association is a medical facility located in Des Moines, Iowa. This center is recognized for care of Breast Cancer, Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Cancer and other specialties. CCOP - Iowa Oncology Research Association is involved with conducting 408 clinical trials across 336 conditions. There are 2 research doctors associated with this hospital, such as Joshua Lukenbill and Tara M. Graff.

Area of expertise

1

Breast Cancer

Global Leader

CCOP - Iowa Oncology Research Association has run 82 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
Stage III
ER positive
2

Lung Cancer

Global Leader

CCOP - Iowa Oncology Research Association has run 57 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage I
Stage II

Top PIs

Clinical Trials running at CCOP - Iowa Oncology Research Association

Chronic Lymphocytic Leukemia

Cancer

CLL

Image of trial facility.

Venetoclax + Obinutuzumab

for Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previously treated with fixed duration first-line (IL) therapy of venetoclax in combination with an anti-CD20 antibody +/- X (where X is any additional drug). Adverse events and change in disease activity will be assessed. Venetoclax is an approved drug for the treatment of CLL. Study doctors put the participants in 1 of 2 groups, called cohorts, based on when symptoms of CLL came back after previous treatment in first-line. Approximately 75 adult participants with CLL who have been treated with venetoclax in combination with an anti-CD20 antibody +/- X will be enrolled in the study in approximately 60 sites worldwide. Participants will receive intravenous (IV) obinutuzumab + oral venetoclax (VenG) in 28-day cycles for a total of 6 cycles per cohort, followed by 6 to 18 cycles of venetoclax alone, for a total treatment of 12 to 24 cycles, depending on the cohort. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Recruiting

1 award

Phase 2

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at CCOP - Iowa Oncology Research Association?

Where is CCOP - Iowa Oncology Research Association located?

Who should I call to ask about financial aid or insurance network?

What insurance does CCOP - Iowa Oncology Research Association accept?

What awards or recognition has CCOP - Iowa Oncology Research Association received?